Fahal A H, el Razig S A, Suliman S H, Ibrahim S Z, Tigani A E
Department of Surgery, Faculty of Medicine, University of Khartoum, Sudan.
East Afr Med J. 1995 Jul;72(7):424-6.
One hundred and fifty patients with histologically proven gastrointestinal tract (GIT) cancer, 150 patients with a variety of other malignancies and 150 normal subjects were screened for human immunodeficiency virus (HIV) and hepatitis B sero-markers. Only one patient with nasopharyngeal carcinoma proved to be HIV seropositive. Hepatitis B surface antigen (HBsAg) was detected in 18% (n = 26) of the GIT cancer patients, in 16% (n = 24) of the other cancers group and in 12% (n = 20) of the control. There was no significant difference between the three groups (P > 0.1). The HBsAg was detected mainly in patients with primary hepatocellular (25%), gastric (12%), rectal (10%) and colonic carcinoma (8%). Hepatitis B core antibody (HBc AB) was detected in 12% of the GIT cancer patients, in 11% of the other cancers patients and in 13% of the control. In this study, there was no association between HIV, hepatitis B infections and GIT cancer.
对150例经组织学证实的胃肠道(GIT)癌患者、150例患有各种其他恶性肿瘤的患者和150名正常受试者进行了人类免疫缺陷病毒(HIV)和乙肝血清标志物筛查。仅1例鼻咽癌患者被证实HIV血清学阳性。在GIT癌患者中,18%(n = 26)检测到乙肝表面抗原(HBsAg);在其他癌症组中,16%(n = 24)检测到;在对照组中,12%(n = 20)检测到。三组之间无显著差异(P > 0.1)。HBsAg主要在原发性肝细胞癌(25%)、胃癌(12%)、直肠癌(10%)和结肠癌(8%)患者中检测到。在GIT癌患者中,12%检测到乙肝核心抗体(HBc AB);在其他癌症患者中,11%检测到;在对照组中,13%检测到。在本研究中,HIV、乙肝感染与GIT癌之间无关联。